A randomized trial of cognitive rehabilitation in cancer survivors

The second most frequently reported post-treatment symptom in cancer survivors are concerns about impaired cognition. Despite numerous studies demonstrating significant impairments in a portion of survivors, information on effective treatments remains an emerging area of research. This study examine...

Full description

Saved in:
Bibliographic Details
Published in:Life sciences (1973) 2013-10, Vol.93 (17), p.617-622
Main Authors: Cherrier, M.M., Anderson, K., David, D., Higano, C.S., Gray, H., Church, A., Willis, S.L.
Format: Article
Language:English
Subjects:
Affect
Anxiety - complications
Anxiety - psychology
Attention
bladder
Cancer
central nervous system diseases
Cognition
Cognition Disorders - complications
Cognition Disorders - psychology
Cognition Disorders - rehabilitation
Cognitive rehabilitation
Cognitive Therapy
colon
Controlled trial
Female
Humans
Male
Memory
Middle Aged
Neoplasms - complications
Neoplasms - psychology
Neoplasms - rehabilitation
Neuropsychological Tests
Patient Satisfaction
patients
Psychotherapy, Group
quality of life
Quality of Life - psychology
questionnaires
Survivors - psychology
Working memory
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The second most frequently reported post-treatment symptom in cancer survivors are concerns about impaired cognition. Despite numerous studies demonstrating significant impairments in a portion of survivors, information on effective treatments remains an emerging area of research. This study examined the effectiveness of a group-based cognitive rehabilitation intervention in cancer survivors. This study was a randomized, controlled study of a 7-week cognitive rehabilitation intervention delivered in group format. Participants were evaluated with subjective symptom questionnaires and objective neurocognitive tests prior to and following treatment. Twenty-eight participants (mean age 58years) with a median of 3years (±6years) post-primary/adjuvant treatment and various cancer sites (breast, bladder, prostate, colon, uterine) completed the study. Compared to baseline, the treatment group demonstrated improvements in symptoms of perceived cognitive impairments (p
ISSN:0024-3205
1879-0631
DOI:10.1016/j.lfs.2013.08.011